Targeting mitochondrial defects in kidney cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210944
- Recipient
-
University Of California, LOS Angeles UEI RN64EPNH8JC6 Part of State Of California Controllers Office
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $961,089
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Los Angeles, CA 90024, USA
Award details come from USAspending.gov.
About this award
The University of California, Los Angeles (UCLA) was awarded a $961,089 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420).
The grant will fund research targeting mitochondrial defects in kidney cancer from September 1, 2022 to August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative medical solutions for service members and the general public. This award will advance those goals by investigating potential treatments for kidney cancer at the mitochondrial level over the three year period of performance.
As the prime awardee, UCLA will conduct the research through its Office of Research Administration. The State of California Controllers Office serves as UCLA's parent organization for this federal assistance.
Quick answers
Who received award W81XWH2210944?
W81XWH2210944 was awarded to University Of California, LOS Angeles by Medical Command (Department of the Army) on September 1, 2022.
How much is award W81XWH2210944 worth?
$961,089 has been obligated on W81XWH2210944.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award